Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple SclerosisBy Mario Cazombo / March 26, 2026 Highlights advancement of first-in-class neuroprotective candidate targeting demyelination Read More
Frankenstein’s Index Fund August 6, 2025 / Alternative Investments, Drivers of Value, Economics, General, Investment Topics, Performance Measurement & Evaluation
How GenAI-Powered Synthetic Data Is Reshaping Investment Workflows August 6, 2025 / Artificial Intelligence, Drivers of Value, Future States, General, Investment Topics, Philosophy
